



23 March 2026

Novartis Pharma AG
Basel, Switzerland
CH-4056

Reference: EudraCT 2021-003747-22 Novartis Protocol ID CADPT07A12101.

Phase I, open label, study of B-cell Maturation Antigen (BCMA)-directed CAR- T cells in adult patients with multiple myeloma

No patients were enrolled in the EU/EEA for trial CADPT07A12101. The study was conducted entirely outside the EU/EEA. Accordingly, no results will be posted on EudraCT.